These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 22974582)
21. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma. Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186 [TBL] [Abstract][Full Text] [Related]
22. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542 [TBL] [Abstract][Full Text] [Related]
23. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial. Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438 [TBL] [Abstract][Full Text] [Related]
24. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma. Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252 [TBL] [Abstract][Full Text] [Related]
25. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593 [TBL] [Abstract][Full Text] [Related]
26. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT. Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915 [TBL] [Abstract][Full Text] [Related]
27. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation. Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS; Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034 [TBL] [Abstract][Full Text] [Related]
28. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Rosiñol L; Oriol A; Teruel AI; de la Guía AL; Blanchard M; de la Rubia J; Granell M; Sampol M; Palomera L; González Y; Etxebeste M; Martínez-Martínez R; Hernández MT; de Arriba F; Alegre A; Cibeira M; Mateos M; Martínez-López J; Lahuerta JJ; San Miguel J; Bladé J Leukemia; 2017 Sep; 31(9):1922-1927. PubMed ID: 28111466 [TBL] [Abstract][Full Text] [Related]
29. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476 [TBL] [Abstract][Full Text] [Related]
30. Multiple myeloma: chemotherapy or transplantation in the era of new drugs. Palumbo A; Rajkumar SV Eur J Haematol; 2010 May; 84(5):379-90. PubMed ID: 20345446 [TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of apoptotic index in multiple myeloma patients treated by conventional therapy and novel agents, thalidomide and bortezomib. Minarik J; Scudla V; Ordeltova M; Bacovsky J; Pika T; Langova K Eur J Haematol; 2009 Dec; 83(6):528-34. PubMed ID: 19624720 [TBL] [Abstract][Full Text] [Related]
32. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation]. Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701 [TBL] [Abstract][Full Text] [Related]
33. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma. Moreau P; Giralt SA Leuk Res; 2012 Nov; 36 Suppl 1():S13-8. PubMed ID: 23176719 [TBL] [Abstract][Full Text] [Related]
34. An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. Boccadoro M; Tarella C; Palumbo A; Argentino C; Triolo S; Dominietto A; Callea V; Lauta VM; Molica S; Musto P; Marmont F; Gianni AM; Pileri A Haematologica; 1999 Oct; 84(10):905-10. PubMed ID: 10509038 [TBL] [Abstract][Full Text] [Related]
35. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187 [TBL] [Abstract][Full Text] [Related]
36. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Harousseau JL; Attal M; Leleu X; Troncy J; Pegourie B; Stoppa AM; Hulin C; Benboubker L; Fuzibet JG; Renaud M; Moreau P; Avet-Loiseau H Haematologica; 2006 Nov; 91(11):1498-505. PubMed ID: 17043025 [TBL] [Abstract][Full Text] [Related]
37. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. Cavo M; Tosi P; Zamagni E; Cellini C; Tacchetti P; Patriarca F; Di Raimondo F; Volpe E; Ronconi S; Cangini D; Narni F; Carubelli A; Masini L; Catalano L; Fiacchini M; de Vivo A; Gozzetti A; Lazzaro A; Tura S; Baccarani M J Clin Oncol; 2007 Jun; 25(17):2434-41. PubMed ID: 17485707 [TBL] [Abstract][Full Text] [Related]
38. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039 [TBL] [Abstract][Full Text] [Related]
39. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma. Galli M; Nicolucci A; Valentini M; Belfiglio M; Delaini F; Crippa C; Barbui AM; Giussani U; Rambaldi A; Barbui T Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437 [TBL] [Abstract][Full Text] [Related]
40. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ; Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]